Bladder carcinoma in situ

This study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…

This study tests two drugs, durvalumab and monalizumab, given together to people with a type of bladder cancer that has not gotten better with standard treatment. The goal is to see if the combination can make the cancer disappear or stop it from growing. About 60 adults will tak…

This study tests a new drug called MK-3120 for high-risk non-muscle invasive bladder cancer. After standard tumor removal, 45 participants will receive the drug directly into the bladder. The main goals are to check safety and how well people tolerate it, while also looking at tu…

This program provides early access to cretostimogene grenadenorepvec, a virus-based therapy, for patients with non-muscle invasive bladder cancer that has not responded to standard BCG treatment. Eligible participants have a specific type of bladder cancer (CIS with or without hi…

This study tests a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle layer but is likely to return. The drug is given directly into the bladder, sometimes with other medicines like BCG or sasanlimab. The trial has three parts …

This phase 2 study is testing a new treatment called TARA-002 for people with a type of high-grade bladder cancer that hasn't spread into the muscle. The treatment is given directly into the bladder through a catheter once a week for 6 weeks. The study will include about 131 adul…

This phase 3 trial tests whether a new drug, TARA-002, works better than standard chemotherapy for a type of early-stage bladder cancer. About 284 adults who have not received BCG therapy will be randomly assigned to receive either TARA-002 or chemotherapy directly into the bladd…

This early-stage trial tests a new drug called PPM, which are tiny particles loaded with the chemotherapy drug paclitaxel and coated with a molecule (PLZ4) that helps them target bladder cancer cells. The drug is given directly into the bladder through a catheter once a week for …

This study tests a new drug called EG-70 (detalimogene) for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The drug is given directly into the bladder through a catheter. The trial includes patients whose cancer did not respond to standard BCG therapy…

This phase 3 trial is testing a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or combined with chemotherapy or immunotherapy. It is for people with a type of bladder cancer that has not responded to standard BCG therapy. The study aim…

This phase 2 trial is testing a treatment called cretostimogene grenadenorepvec, a modified virus designed to infect and destroy cancer cells, in 16 people with high-risk bladder cancer that has not responded to standard BCG therapy. The study aims to see if the treatment can mak…

This phase 2 trial is testing whether two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder can treat high-risk bladder cancer that did not respond to standard BCG therapy. About 174 adults will receive weekly treatments for 6 weeks, then monthly for …

This early-stage trial is testing a new version of the BCG therapy, made from a genetically modified bacterium, for people with non-muscle invasive bladder cancer (NMIBC) who have not received BCG before. The treatment is given directly into the bladder through a catheter. The st…

This early-stage trial tests a new treatment called PLZ4-coated paclitaxel-loaded micelles (PPM) for people with non-muscle invasive bladder cancer that has come back or not responded to standard therapy. PPM is a nanoparticle designed to deliver chemotherapy directly to tumor ce…

This study tests a new drug called Ruvidar, given directly into the bladder, for people with a type of bladder cancer that did not respond to or could not tolerate standard BCG therapy. About 90 adults will receive up to three treatment sessions. The main goal is to see if the dr…

This study compares a home-based physical activity program delivered through the ExerciseRx app to health education alone in 100 adults with non-muscle invasive bladder cancer. Participants will use a Fitbit to track steps, and the app will set personalized goals and provide enco…

This study tests whether giving chemotherapy directly into the bladder at home is safe and acceptable for people with non-muscle invasive bladder cancer. About 40 participants will receive their usual medications—such as BCG, gemcitabine, docetaxel, or mitomycin—at home instead o…